EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The past, present, and future of Alzheimer's disease—part 3: the future

Ricardo Nitrini iD, Leonel Tadao Takada iD, Sonia Maria Dozzi Brucki iD

Arquivos de Neuro-Psiquiatria · 01.06.2026 · 84 (06) · 001-010

DOI: 10.1055/s-0046-1824435 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arquivos de Neuro-Psiquiatria, erschienen am 01.06.2026. Verfasst von Ricardo Nitrini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e Comportamental, São Paulo SP, Brazil. Hauptthemen laut MEDLINE: Alzheimer Disease. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractPredicting future advances in science is practically impossible because unexpected discoveries can radically change the march of ongoing processes. Predicting the nearest future may have a slightly greater chance of success. First, the diagnosis of risk factors for Alzheimer's disease (AD), based on the preponderant role of genetics, will be made very early. Diagnosis will be made with biomarkers prior to clinical manifestations. Furthermore, the prevention of AD and of dementia due to AD will be possible with better control of the many risk factors for dementia, healthier lifestyles, multi-target drugs, and genetic therapy. The relationship between AD and aging will be better understood, opening possibilities for intervention in aging itself. As the pathophysiology of AD is not unique, treatment will be individualized, according to the stage and characteristics of the disease. Most clinical trials will have surrogate markers as primary outcomes. Treatments to decrease the velocity or arrest the evolution of mild cognitive impairment (MCI) and mild dementia caused by AD will be available. Additionally, artificial intelligence (AI) will aid in the diagnosis and selection of the best treatments. Access to the new methods for diagnosing and treating AD is currently limited to a small parcel of the population, especially in low- and middle-income countries, because of their high costs. Due to the high prevalence of AD, it is possible these will become less expensive in the future. The possibility of reversing dementia once it has set in will probably have to wait for longer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansRisk FactorsBiomarkersForecasting

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, Grupo de Neurologia Cognitiva e Comportamental, São Paulo SP, Brazil.

ORCID-Profile: Ricardo Nitrini, Leonel Tadao Takada, Sonia Maria Dozzi Brucki

Zitieren

APA

Nitrini, R., Takada, L. T., & Brucki, S. M. D. (2026). The past, present, and future of Alzheimer's disease—part 3: the future. Arquivos de Neuro-Psiquiatria, 84(06), 001-010. https://doi.org/10.1055/s-0046-1824435

Vancouver

Nitrini R, Takada LT, Brucki SMD. The past, present, and future of Alzheimer's disease—part 3: the future. Arquivos de Neuro-Psiquiatria. 2026;84(06):001-010. doi:10.1055/s-0046-1824435

BibTeX
@article{Nitrini2026,
  author = {Nitrini, Ricardo and Takada, Leonel Tadao and Brucki, Sonia Maria Dozzi},
  title = {The past, present, and future of Alzheimer's disease—part 3: the future},
  journal = {Arquivos de Neuro-Psiquiatria},
  year = {2026},
  volume = {84},
  number = {06},
  pages = {001--010},
  doi = {10.1055/s-0046-1824435}
}
Kostenlos starten →